Division of Orthopaedic Surgery, University of Toronto, Toronto, Canada.
Oxford Trauma Unit, John Radcliffe Hospital, Oxford, UK.
Bone Joint J. 2021 Dec;103-B(12):1783-1790. doi: 10.1302/0301-620X.103B12.BJJ-2021-0495.R2.
Total hip arthroplasty (THA) with dual-mobility components (DM-THA) has been shown to decrease the risk of dislocation in the setting of a displaced neck of femur fracture compared to conventional single-bearing THA (SB-THA). This study assesses if the clinical benefit of a reduced dislocation rate can justify the incremental cost increase of DM-THA compared to SB-THA.
Costs and benefits were established for patients aged 75 to 79 years over a five-year time period in the base case from the Canadian Health Payer's perspective. One-way and probabilistic sensitivity analysis assessed the robustness of the base case model conclusions.
DM-THA was found to be cost-effective, with an estimated incremental cost-effectiveness ratio (ICER) of CAD $46,556 (£27,074) per quality-adjusted life year (QALY). Sensitivity analysis revealed DM-THA was not cost-effective across all age groups in the first two years. DM-THA becomes cost-effective for those aged under 80 years at time periods from five to 15 years, but was not cost-effective for those aged 80 years and over at any timepoint. To be cost-effective at ten years in the base case, DM-THA must reduce the risk of dislocation compared to SB-THA by at least 62%. Probabilistic sensitivity analysis showed DM-THA was 58% likely to be cost-effective in the base case.
Treating patients with a displaced femoral neck fracture using DM-THA components may be cost-effective compared to SB-THA in patients aged under 80 years. However, future research will help determine if the modelled rates of adverse events hold true. Surgeons should continue to use clinical judgement and consider individual patients' physiological age and risk factors for dislocation. Cite this article: 2021;103-B(12):1783-1790.
与传统单轴承全髋关节置换术(SB-THA)相比,双动组件全髋关节置换术(DM-THA)可降低股骨颈骨折伴股骨颈移位患者脱位的风险。本研究评估降低脱位率的临床获益是否可以证明 DM-THA 比 SB-THA 增加的成本是合理的。
从加拿大医疗支付方的角度,在基况下,对 75-79 岁的患者在五年时间内建立成本和效益。单因素敏感性分析和概率敏感性分析评估了基础模型结论的稳健性。
DM-THA 具有成本效益,估计增量成本效益比(ICER)为每质量调整生命年(QALY)46556 加元(27074 英镑)。敏感性分析表明,在最初的两年内,DM-THA 在所有年龄段都不具有成本效益。对于 80 岁以下的患者,在 5 至 15 年的时间内,DM-THA 具有成本效益,但对于 80 岁及以上的患者,在任何时间点都不具有成本效益。在基况下,要在 10 年内具有成本效益,DM-THA 必须使与 SB-THA 相比,脱位风险降低至少 62%。概率敏感性分析表明,在基况下,DM-THA 有 58%的可能性具有成本效益。
与 SB-THA 相比,在 80 岁以下的股骨颈骨折伴股骨颈移位患者中使用 DM-THA 组件治疗可能具有成本效益。然而,未来的研究将有助于确定所建不良事件发生率是否成立。外科医生应继续使用临床判断,并考虑患者的生理年龄和脱位风险因素。引用本文:2021;103-B(12):1783-1790。